Antitrust Antitrust

Yangtze River Pharmaceutical's RPM probe concerns multiple drugs in China

By MLex Staff
  • 07 Jan 2021 02:44
  • 07 Jan 2021 02:46
Yangtze River Pharmaceutical, one of China's largest pharmaceutical makers, is accused of controlling resale prices of multiple drugs in an ongoing investigation by the country's competition regulator, MLex has learned.
The Chinese pharma giant allegedly imposed resale price maintenance, or RPM, restrictions in some commonly used drugs, prompting a state-level

To view the latest version of this document and thousands of others like it, sign-in to MLex or register for a free trial.

Discover MLex

Stay on top of global regulatory developments

Latest News